The patients of the TCGA-PAAD cohort were divided into two groups based on the same percentage as in our cohort, (high CFB mRNA (119/175: 68 %) and low CFB mRNA (56/175: 32 %)). The gene discussed is CFB; the disease is pancreatic adenocarcinoma.